Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 10/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | MYC | P01106 | 1/20 | 0.55 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14209180 | 0.95 | APEX1 (0.69) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL14209182 | 0.91 | APEX1 (0.65) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL1292147 | 0.91 | APEX1 (0.66) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL1292202 | 0.90 | LMNA (0.63) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL14232682 | 0.89 | APEX1 (0.69) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL1292117 | 0.89 | LMNA (0.56) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL1292258 | 0.87 | TP53 (0.58) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL1292107 | 0.87 | LMNA (0.56) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL13735656 | 0.87 | APEX1 (0.83) | APEX1MEN1KMT2AKDM4EUSP2 | |
| SCHEMBL14209212 | 0.86 | APEX1 (0.69) | APEX1MEN1KMT2AKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589970-A4 | PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO ¬2,3-C PYRIDINE DERITIVES AND USE THEREOF | RIMONYX PHARMACEUTICALS LTD (IL) | 2008-05-21 | — | — | EP | claimed |
| US-7365080-B2 | 2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide; inhibiting interactions between effector cell adhesion molecules (ECAM), as selectins, and glycosaminoglycans (GAG), as heparan sulfate glycosaminoglycans (HS-GAGs); autoimmune diseases | RIMONYX PHARMACEUTICALS LTD. (IL) | 2008-04-29 | — | — | US | claimed |
| JP-2006516610-A | — | — | 2006-07-06 | — | — | JP | claimed |
| US-20060135529-A1 | Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof | RIMONYX PHARMACEUTICALS LTD (IL) | 2006-06-22 | — | — | US | claimed |
| EP-1589970-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO [2,3-C]PYRIDINE DERITIVES AND USE THEREOF | Rimonyx Pharmaceuticals Ltd. (IL) | 2005-11-02 | — | — | EP | claimed |
| WO-2004069149-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO[2,3-C]PYRIDINE DERIVATIVES AND USE THEREOF | RIMONYX PHARMACEUTICALS LTD. (IL) | 2004-08-19 | — | — | WO | claimed |
| WO-2012045114-A1 | AGENTS AND METHODS FOR TREATING HEMATOLOGIC CONDITIONS | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-04-12 | — | — | WO | disclosed |
| EP-1589970-A4 | PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO ¬2,3-C PYRIDINE DERITIVES AND USE THEREOF | RIMONYX PHARMACEUTICALS LTD (IL) | 2008-05-21 | — | — | EP | disclosed |
| US-7365080-B2 | 2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide; inhibiting interactions between effector cell adhesion molecules (ECAM), as selectins, and glycosaminoglycans (GAG), as heparan sulfate glycosaminoglycans (HS-GAGs); autoimmune diseases | RIMONYX PHARMACEUTICALS LTD. (IL) | 2008-04-29 | — | — | US | disclosed |
| US-7365080-B2 | 2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide; inhibiting interactions between effector cell adhesion molecules (ECAM), as selectins, and glycosaminoglycans (GAG), as heparan sulfate glycosaminoglycans (HS-GAGs); autoimmune diseases | RIMONYX PHARMACEUTICALS LTD. (IL) | 2008-04-29 | — | — | US | disclosed |
| US-20060135529-A1 | Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof | RIMONYX PHARMACEUTICALS LTD (IL) | 2006-06-22 | — | — | US | disclosed |
| EP-1589970-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO [2,3-C]PYRIDINE DERITIVES AND USE THEREOF | Rimonyx Pharmaceuticals Ltd. (IL) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069149-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO[2,3-C]PYRIDINE DERIVATIVES AND USE THEREOF | RIMONYX PHARMACEUTICALS LTD. (IL) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135529-A1 | Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof | CD4, SELPLG, ITGAM | APEX1 3872/4885MEN1 3465/4885KMT2A 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.